Sept. 12 Clinical Quick Takes: Celgene meets in Phase III for AML maintenance therapy; plus Roche, Tocagen, Adverum, Daiichi Sankyo, Apple, Navitor

On Phase III AML meet, Celgene to submit regulatory applications 1H20
Celgene Corp. (NASDAQ:CELG) plans to submit regulatory applications for CC-486 next half after the cytosine nucleoside analog met the primary and secondary endpoints in the Phase III QUAZAR AML-001 trial as a maintenance therapy in newly diagnosed acute myelogenous leukemia patients. CC-486 extended overall survival, the primary endpoint, and improved relapse-free survival, a key secondary endpoint, vs. placebo.

Roche's mAb reduces relapse risk in rare

Read the full 742 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE